Scientists once hoped that blocking β-secretase would slow or prevent Alzheimer’s disease. Then came the rude awakening. The inhibitors caused the very thing they were supposed to prevent—cognitive ...

Detailed clinical and biomarker data say lanabecestat trial worked, the drug did not. All eyes are now on elenbecestat and umibecestat. These two compounds are more selective for BACE1 over BACE2.

CHARLOTTE, N.C.--(BUSINESS WIRE)--BACE, LLC, a leading global equipment manufacturer, technology innovator and national service provider for the recycling and waste management industry, announces it ...

One of the last major, late-stage attempt at stopping Alzheimer’s disease (AD) using a BACE inhibitor has ended up on the trash pile with so many others. Earlier this year, Biogen and partner Eisai ...

Things really took off at the 2025 National Business Aviation Association’s Business Aviation Convention & Exhibition (NBAA-BACE)—with no signs of any major turbulence. The civil aviation trade show ...

While Eisai and Biogen’s oral BACE inhibitor elenbecestat was able to demonstrate a reduction in amyloid beta levels in 35 patients with Alzheimer’s disease, it failed to slow the decline of clinical ...

CARY, N.C., April 30, 2021 /PRNewswire/ -- Phoenix Cardiac Devices, Inc., an innovator in cardiovascular medical device research and development, today presented pivotal data for its BACE™ (Basal ...